Saito Yoshiyuki, Matsuzu Kenichi, Abdelhamid Ahmed Amr H, Inoue Kosuke, Shibuya Hiroshi, Matsui Ai, Kuga Yoko, Ono Reiko, Yoshioka Kana, Masaki Chie, Akaishi Junko, Hames Kiyomi Y, Okamura Ritsuko, Tomoda Chisato, Suzuki Akifumi, Kitagawa Wataru, Nagahama Mitsuji, Sugino Kiminori, Takami Hiroshi, Randolph Gregory W, Ito Koichi
Department of Surgery, Ito Hospital, Tokyo, Japan.
Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston.
JAMA Otolaryngol Head Neck Surg. 2025 Feb 1;151(2):105-112. doi: 10.1001/jamaoto.2024.3860.
The management of papillary thyroid carcinoma (PTC), particularly in cases with clinically apparent lateral neck lymph node metastasis (cN1b), remains an area of debate. The surgical options for PTC, including total thyroidectomy and lobectomy, have distinct impacts on patients' outcomes and quality of life.
To compare survival and recurrence outcomes between patients who underwent a lobectomy plus ipsilateral lateral neck dissection (LND) and those who underwent a total thyroidectomy plus ipsilateral LND for intermediate-risk cN1b PTC with both primary tumors and lymph node metastases in the ipsilateral neck region.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted at Ito Hospital, Tokyo, Japan. Patients who underwent surgery for PTC between January 2005 and December 2012 were included, and those with high-risk PTCs and concurrent other thyroid cancers were excluded. Data were analyzed from April to August 2024.
Lobectomy plus LND vs total thyroidectomy plus LND.
An inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier analysis and a Cox proportional hazards regression analysis were performed to compare the patients' overall survival, recurrence-free survival (RFS), and modified RFS (which considered the potential need for a future contralateral lobectomy).
Of 401 included patients, 317 (79.1%) were female, and the median (IQR) age was 47 (36-59) years. A total of 157 patients underwent lobectomy plus ipsilateral LND and 244 underwent total thyroidectomy plus ipsilateral LND. The median (IQR) follow-up time was 13.0 (11.2-15.0) years. The IPTW-adjusted overall survival rates at 5, 10, and 15 years were 98.0% (95% CI, 93.9-99.3), 97.5% (95% CI, 93.2-99.1), and 96.8% (95% CI, 92.2-98.7), respectively, for the lobectomy group vs 99.4% (95% CI, 97.0-99.9), 97.4% (95% CI, 94.4-98.8), and 96.9% (95% CI, 93.3-98.5), respectively, for the total thyroidectomy group (hazard ratio [HR], 1.10; 95% CI, 0.35-3.47). The IPTW-adjusted RFS rates at 5, 10, and 15 years were 93.8% (95% CI, 88.5-96.7), 88.4% (95% CI, 82.0-92.6), and 84.1% (95% CI, 76.8-89.3), respectively, for the lobectomy group vs 95.4% (95% CI, 91.8-97.4), 92.9% (95% CI, 88.8-95.5), and 87.8% (95% CI, 80.8-92.4), respectively, for the total thyroidectomy group (HR, 1.41; 95% CI, 0.79-2.54). The IPTW-adjusted modified RFS rates at 5, 10, and 15 years were 96.7% (95% CI, 92.2-98.6), 93.8% (95% CI, 88.5-96.7), and 88.9% (95% CI, 82.4-93.1), respectively, for the lobectomy group vs 95.4% (95% CI, 91.8-97.4), 92.9% (95% CI, 88.8-95.5), and 87.8% (95% CI, 80.8-92.4), respectively, for the total thyroidectomy group (HR, 0.93; 95% CI, 0.49-1.76).
In this study, for these selected intermediate-risk cN1b PTC cases, total thyroidectomy and lobectomy provided comparable outcomes in terms of prognosis and recurrence. These data may help inform future guideline revisions and support joint decision-making between patients and their clinicians.
甲状腺乳头状癌(PTC)的治疗,尤其是临床明显的侧颈部淋巴结转移(cN1b)病例,仍是一个存在争议的领域。PTC的手术选择,包括全甲状腺切除术和甲状腺叶切除术,对患者的预后和生活质量有不同影响。
比较接受甲状腺叶切除术加同侧侧颈部淋巴结清扫术(LND)的患者与接受全甲状腺切除术加同侧LND的患者在伴有同侧颈部区域原发性肿瘤和淋巴结转移的中度风险cN1b PTC患者中的生存和复发结果。
设计、设置和参与者:这项回顾性队列研究在日本东京的伊藤医院进行。纳入了2005年1月至2012年12月期间接受PTC手术的患者,排除了高危PTC患者和同时患有其他甲状腺癌的患者。数据于2024年4月至8月进行分析。
甲状腺叶切除术加LND与全甲状腺切除术加LND。
进行逆概率治疗权重(IPTW)调整的Kaplan-Meier分析和Cox比例风险回归分析,以比较患者的总生存期、无复发生存期(RFS)和改良RFS(考虑未来对侧甲状腺叶切除术的潜在需求)。
在纳入的401例患者中,317例(79.1%)为女性,中位(IQR)年龄为47(36 - 59)岁。共有157例患者接受了甲状腺叶切除术加同侧LND,244例接受了全甲状腺切除术加同侧LND。中位(IQR)随访时间为13.0(11.2 - 15.0)年。甲状腺叶切除术组5年、10年和15年的IPTW调整总生存率分别为98.0%(95%CI,93.9 - 99.3)、97.5%(95%CI,93.2 - 99.1)和96.8%(95%CI,92.2 - 98.7),而全甲状腺切除术组分别为99.4%(95%CI,97.0 - 99.9)、97.4%(95%CI,94.4 - 98.8)和96.9%(95%CI,93.3 - 98.5)(风险比[HR],1.10;95%CI,0.35 - 3.47)。甲状腺叶切除术组5年、10年和15年的IPTW调整RFS率分别为93.8%(95%CI,88.5 - 96.7)、88.4%(95%CI,82.0 - 92.6)和84.1%(95%CI,76.8 - 89.3),全甲状腺切除术组分别为95.4%(95%CI,91.8 - 97.4)、92.9%(95%CI,88.8 - 95.5)和87.8%(95%CI,80.8 - 92.4)(HR,1.41;95%CI,0.79 - 2.54)。甲状腺叶切除术组5年、10年和15年的IPTW调整改良RFS率分别为96.7%(95%CI,92.2 - 98.6)、93.8%(95%CI,88.5 - 96.7)和88.9%(95%CI,82.4 - 93.1),全甲状腺切除术组分别为95.4%(95%CI,91.8 - 97.4)、92.9%(95%CI,88.8 - 95.5)和87.8%(95%CI,80.8 - 92.4)(HR,0.93;95%CI,0.49 - 1.76)。
在本研究中,对于这些选定的中度风险cN1b PTC病例,全甲状腺切除术和甲状腺叶切除术在预后和复发方面提供了可比的结果。这些数据可能有助于为未来的指南修订提供信息,并支持患者与其临床医生之间的共同决策。